Literature DB >> 11850804

Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells.

Sumi Dinda1, Amelita Sanchez, Virinder Moudgil.   

Abstract

T47D cells represent an estrogen-responsive human ductal carcinoma cell line which expresses detectable levels of estrogen receptor (ER). We have previously shown that estradiol (E(2)) treatment of T47D cells causes an increase in the level of p53 and a concomitant phosphorylation of retinoblastoma protein (pRb). In the present study, we have analysed the expression of p53 and phosphorylation state of pRb and compared the effects of E(2) and triiodothyronine (T(3)) on these phenomena. Cells were grown in a medium containing charcoal-treated serum to deplete the levels of endogenous steroids. Upon confluency, the cells were treated with T(3) (10(-12) to 10(-7) M) for 24 h and the presence of p53 and pRb was detected by Western analysis. E(2) treatment of cells caused a 2-3-fold increase in the level of p53. Presence of T(3) in the medium caused a gradual increase in the level of p53 in a concentration-dependent manner. Under the above conditions, pRb was phosphorylated (detected as an upshift during SDS-PAGE) in the presence of E(2) and T(3). Supplementation of growth medium with T(3) (1 microM) caused an increase in the rate of proliferation of T47D cells and induced hyperphosphorylation of pRb within 4 h; this effect was maintained for up to 12 h. When ICI 164 384 (ICI) (1 microM), an ER antagonist, was combined with E(2) (1 nM) or T(3) (1 microM), effects of hormones on cell proliferation and hyperphosphorylation of pRb were blocked. Western analysis of p53 was supplemented with its cytolocalization by immuno-labeling using laser scanning confocal fluorescence microscopy, which revealed an ICI-sensitive increase in the abundance of p53 in hormone-treated cells. Steroid binding analysis revealed lack of competition by T(3) for the [(3)H]E(2) binding. These results indicate that T(3) regulates T47D cell cycle progression and proliferation raising the p53 level and causing hyperphosphorylation of pRb by a common mechanism involving ER and T(3) receptor (T(3)R)-mediated pathways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850804     DOI: 10.1038/sj.onc.1205136

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Thyroid Hormone Receptor β Inhibits Self-Renewal Capacity of Breast Cancer Stem Cells.

Authors:  Irene López-Mateo; Elvira Alonso-Merino; Cristian Suarez-Cabrera; Jeong Won Park; Sheue-Yann Cheng; Susana Alemany; Jesús M Paramio; Ana Aranda
Journal:  Thyroid       Date:  2019-12-30       Impact factor: 6.568

2.  Mediator subunit MED1 modulates intranuclear dynamics of the thyroid hormone receptor.

Authors:  Matthew R Femia; Rochelle M Evans; Jibo Zhang; Xiaopeng Sun; Caroline J Lebegue; Vincent R Roggero; Lizabeth A Allison
Journal:  J Cell Biochem       Date:  2019-11-06       Impact factor: 4.429

Review 3.  Triiodothyronine and breast cancer.

Authors:  Maria Teresa De Sibio; Miriane de Oliveira; Fernanda Cristina Fontes Moretto; Regiane Marques Castro Olimpio; Sandro José Conde; Aline Carbonera Luvizon; Célia Regina Nogueira
Journal:  World J Clin Oncol       Date:  2014-08-10

4.  Early-onset breast cancer in a woman with Graves' disease.

Authors:  James E Siegler; Xinying Li; Steven D Jones; Emad Kandil
Journal:  Int J Clin Exp Med       Date:  2012-08-22

Review 5.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

6.  Antithyroid peroxidase antibody positivity is associated with lower incidence of metastasis in breast cancer.

Authors:  Yasemin Kemal; Guzin Demirag; Kubilay Ekiz; Idris Yucel
Journal:  Mol Clin Oncol       Date:  2015-03-02

7.  Breast Cancer Risk in Postmenopausal Women with Medical History of Thyroid Disorder in the Women's Health Initiative.

Authors:  Chien-Hsiang Weng; Erin R Okawa; Mary B Roberts; Sue K Park; Christopher B Umbricht; JoAnn E Manson; Charles B Eaton
Journal:  Thyroid       Date:  2020-02-03       Impact factor: 6.568

8.  A case-control study of levothyroxine and the risk of colorectal cancer.

Authors:  Gad Rennert; Hedy S Rennert; Mila Pinchev; Stephen B Gruber
Journal:  J Natl Cancer Inst       Date:  2010-03-19       Impact factor: 13.506

9.  Hyperthyroidism, Hypothyroidism, and Cause-Specific Mortality in a Large Cohort of Women.

Authors:  Neige M Y Journy; Marie-Odile Bernier; Michele M Doody; Bruce H Alexander; Martha S Linet; Cari M Kitahara
Journal:  Thyroid       Date:  2017-07-06       Impact factor: 6.568

10.  Early-onset breast disease: case of a Grave condition with a favorable prognosis.

Authors:  James E Siegler; Steven D Jones; Emad Kandil
Journal:  Int J Clin Exp Med       Date:  2012-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.